CU22613A1 - USE OF EPIDERMIC GROWTH FACTOR FOR THE TREATMENT OF ACNE - Google Patents

USE OF EPIDERMIC GROWTH FACTOR FOR THE TREATMENT OF ACNE

Info

Publication number
CU22613A1
CU22613A1 CU1994136A CU1994136A CU22613A1 CU 22613 A1 CU22613 A1 CU 22613A1 CU 1994136 A CU1994136 A CU 1994136A CU 1994136 A CU1994136 A CU 1994136A CU 22613 A1 CU22613 A1 CU 22613A1
Authority
CU
Cuba
Prior art keywords
treatment
acne
egf
group
patients
Prior art date
Application number
CU1994136A
Other languages
Spanish (es)
Inventor
Bernal Francisco Hernandez
Santana Maria Dolores Castro
Aragon Guillermo Fernandez
Machado Jose Rodriguez
De La Rocha Quevedo Arturo Diaz
Lopez Tania Gonzalez
Saura Pedro Antonio Lopez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU1994136A priority Critical patent/CU22613A1/en
Priority to PCT/NL1995/000392 priority patent/WO1996016669A1/en
Priority to ARP950100314A priority patent/AR002002A1/en
Publication of CU22613A1 publication Critical patent/CU22613A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/86—Products or compounds obtained by genetic engineering

Abstract

La presente invención está relacionada con la rama de la Medicina y en particular con el empleo del Factor de Crecimiento Epidérmico (EGF) humano y recombinante en la fabricación de un medicamento para el tratamiento del acné. Su objetivo técnico es lograr un producto eficaz para el tratamiento de esta enfermedad crónica de la piel con implicaciones estéticas y psicológicas, demostrándose la utilidad de este principio activo para la fabricación de un medicamento para el tratamiento de dicha patología en un ensayo clínico realizado a doble ciego. De un total de 30 pacientes con acné activo tratados diariamente durante 90 días, se determinó el grado de afección según la escala de 8 grados del Colegio Médico Universitario Inglés, al inicio, a los 45 días y al finalizar el tratamiento. El grupo tratado con EGF presentó mejoría significativa (p < 0.01) con respecto al que recibió placebo, encontrándose en el grupo que utilizó EGF una mejoría general en 23 pacientes (79.3%), destacándose de ellos 15 (51.7%) mucho mejor y 8 (27.5%) mejor. Ningún paciente empeoró. Esta invención puede emplearse como alternativa terapéutica o complementaria para el tratamiento del acné crónico.The present invention is related to the branch of Medicine and in particular to the use of recombinant human Epidermal Growth Factor (EGF) in the manufacture of a medicine for the treatment of acne. Its technical objective is to achieve an effective product for the treatment of this chronic skin disease with aesthetic and psychological implications, demonstrating the usefulness of this active ingredient for the manufacture of a drug for the treatment of said pathology in a clinical trial carried out twice blind. From a total of 30 patients with active acne treated daily for 90 days, the degree of affection was determined according to the 8-degree scale of the English University Medical College, at the beginning, at 45 days and at the end of treatment. The group treated with EGF showed significant improvement (p <0.01) with respect to the group receiving placebo, with the group using EGF finding a general improvement in 23 patients (79.3%), with 15 (51.7%) standing out much better and 8 (27.5%) better. No patient worsened. This invention can be used as a therapeutic or complementary alternative for the treatment of chronic acne.

CU1994136A 1994-11-25 1994-11-25 USE OF EPIDERMIC GROWTH FACTOR FOR THE TREATMENT OF ACNE CU22613A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CU1994136A CU22613A1 (en) 1994-11-25 1994-11-25 USE OF EPIDERMIC GROWTH FACTOR FOR THE TREATMENT OF ACNE
PCT/NL1995/000392 WO1996016669A1 (en) 1994-11-25 1995-11-17 Use of human recombinant epidermal growth factor in the manufacture of a medicament for treating acne
ARP950100314A AR002002A1 (en) 1994-11-25 1995-11-24 USE OF THE EPIDERMIC GROWTH FACTOR IN THE MANUFACTURE OF A MEDICINE IN THE FORM OF HYDROPHILIC CREAM FOR THE TREATMENT OF ACNE.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1994136A CU22613A1 (en) 1994-11-25 1994-11-25 USE OF EPIDERMIC GROWTH FACTOR FOR THE TREATMENT OF ACNE

Publications (1)

Publication Number Publication Date
CU22613A1 true CU22613A1 (en) 2000-02-10

Family

ID=46093359

Family Applications (1)

Application Number Title Priority Date Filing Date
CU1994136A CU22613A1 (en) 1994-11-25 1994-11-25 USE OF EPIDERMIC GROWTH FACTOR FOR THE TREATMENT OF ACNE

Country Status (3)

Country Link
AR (1) AR002002A1 (en)
CU (1) CU22613A1 (en)
WO (1) WO1996016669A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3148570A4 (en) * 2014-05-29 2018-02-14 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical composition for preventing or treating skin rash

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3380839D1 (en) * 1983-11-02 1989-12-21 J C R Kabushiki Kaisha Also Kn Ophthalmic preparations
US5023090A (en) * 1989-08-16 1991-06-11 Levin Robert H Topical compositions containing LYCD and other topically active medicinal ingredients for the treatment of ACNE
CN1083371A (en) * 1993-01-03 1994-03-09 周至惠 Acne, folliculitis, erythra special nursing agent

Also Published As

Publication number Publication date
AR002002A1 (en) 1998-01-07
WO1996016669A1 (en) 1996-06-06

Similar Documents

Publication Publication Date Title
ES2549329T3 (en) Topical administration of arginine for pain treatment
CY1121447T1 (en) COMPOSITIONS FOR INCREASING TELEVISION ACTIVITY
HK1035336A1 (en) Use of preparations for the application of antiseptic agents and/or agents promoting the healing of wounds to the lower respiratory tract
CY1105818T1 (en) USES OF ET743 IN THE THERAPEUTIC TREATMENT OF CANCER
HU9300636D0 (en) Medical preparatives, method for producing them and their applications as analgetic and/or febrifuge in human and veterinary medicine
DE69316660T2 (en) Terfanadine metabolites and their optically pure isomers for the treatment of allergic diseases
ES2157005T3 (en) USE OF BOSWELLICO ACID AND ITS DERIVATIVES FOR THE INHIBITION OF THE NORMAL AND ELEVATED ACTIVITY OF ELASTASA DE LEUCOCITOS OR PLASMINA.
DE60018409D1 (en) USE OF ANTISEPTICA FOR THE PREPARATION OF MEDICAMENTS FOR THE PROPHYLAXIS AND THE TREATMENT OF INFECTIONS AND / OR FUNCTIONAL TISSUE FORMATIONS IN THE BODY&#39;S INSECTS
DK1289535T3 (en) Apoptotic devices for use in the treatment of neurodegenerative and other neurological diseases
DE60043886D1 (en) FORMULATIONS WITH POVIDONE IOD FOR THE TREATMENT OF WOUNDS
CU22613A1 (en) USE OF EPIDERMIC GROWTH FACTOR FOR THE TREATMENT OF ACNE
RU2005131578A (en) APLIDINE FOR TREATMENT OF MULTIPLE MYELOMA
ATE224727T1 (en) FACTOR XIII FOR THE TREATMENT OF SKIN WOUNDS
Van Assen et al. Antonius Mathijsen, the discoverer of the plaster bandage
Patel et al. Management of Non Healing Ulcer with Local Application of Yastimadhu Ghrita (Glycyrrhiza Glabra L.): A Single Case Study
CN1321647C (en) Medicine for wound healing and preparation method thereof
RU31101U1 (en) Device for introducing oxygen into human tissue
Kumari et al. ROLE OF PRIYANGVADI TAILA IN THE MANAGEMENT OF DIABETIC WOUND-A CASE REPORT
Zieliński et al. Patient Treatment Case Description in the Centre for Hyperbaric Oxygen and Wound Treatment in Bydgoszcz
MD3076F1 (en) Method of purulo-necrotic wound treatment to patients with diabetic foot
CA2382315A1 (en) Antineoplastic extract from achillea millefolium
RU93038888A (en) WIPE CARBON MATERIAL
Swain Topical 5‐fluorouracil for corns—an effective new treatment
CU22656A1 (en) EFFECTIVE MEDICINAL PREPARATION AGAINST ESCARAS AND EXTERNAL ULCERAS
UA31644A (en) INOL DRUG FOR TREATMENT OF BREAST CANCER